The Peptide Iceberg
You already know BPC-157. You have probably read about TB-500 and the GH secretagogues. Those are the surface layer -- the peptides that dominate Reddit threads and YouTube thumbnails.
But underneath that layer sits an entire class of compounds that barely register in mainstream biohacking discourse. These are the peptides that show up in obscure Russian journals, single-author PubMed entries from the early 2000s, and the occasional conference poster that never became a full paper.
This article is for people who have already done their homework on the popular stuff and want to understand what lives further down the rabbit hole. Fair warning: the further you go, the thinner the evidence gets.
Khavinson Peptides: The Russian Bioregulator Tradition
Vladimir Khavinson has been publishing on short peptides since the 1970s through the Saint Petersburg Institute of Bioregulation and Gerontology. His body of work centers on ultra-short peptides -- typically di-, tri-, and tetrapeptides -- that he claims regulate gene expression in specific tissues.
Pinealon (Ala-Glu-Asp)
A tripeptide marketed as a "pineal gland bioregulator." The proposed mechanism involves penetrating cell membranes and interacting with DNA to modulate melatonin synthesis pathways. A 2011 study in Bulletin of Experimental Biology and Medicine reported that Pinealon increased melatonin production in pinealocyte cell cultures by roughly 30%.
The reality check: Almost all Pinealon research comes from Khavinson's own lab or closely affiliated Russian institutions. Independent Western replication is virtually nonexistent. The cell culture work is interesting but extremely preliminary.
Cortagen (Ala-Glu-Asp-Leu)
A tetrapeptide described as a "cortex bioregulator." Khavinson's group has published data suggesting it promotes neuronal survival and may modulate cortical gene expression. A 2008 paper claimed Cortagen could normalize brain bioelectric activity in aged rats.
The reality check: Same issue as Pinealon -- almost zero independent verification. The leap from rat brain bioelectric readings to meaningful cognitive benefits in humans is enormous.
Epitalon (Ala-Glu-Asp-Gly)
Perhaps the most famous Khavinson peptide. The claim is that Epitalon activates telomerase, thereby extending telomere length and potentially lifespan. A widely cited 2003 study reported telomerase activation in human somatic cells treated with Epitalon.
The reality check: Telomerase activation is a double-edged sword. Cancer cells also rely on telomerase to achieve immortality. The longevity data comes almost entirely from rodent models under Khavinson's supervision. No randomized controlled human trials exist.
Mitochondrial-Derived Peptides
This category is arguably the most scientifically legitimate on this list, with research coming from well-established labs at USC, Albert Einstein College of Medicine, and elsewhere.
MOTS-c
A 16-amino-acid peptide encoded in the mitochondrial genome's 12S rRNA gene. Discovered by Changhan David Lee's group at USC in 2015, MOTS-c appears to function as a mitochondrial signaling molecule that regulates metabolic homeostasis. It activates AMPK, enhances glucose uptake, and has been described as an "exercise mimetic" in animal models.
A 2019 study in Cell Metabolism showed that exercise increases circulating MOTS-c levels in humans, and that MOTS-c translocates to the nucleus during metabolic stress to regulate adaptive gene expression. This is real, peer-reviewed science from credible institutions.
Why it is still underground: MOTS-c is not commercially developed as a therapeutic. It exists in a weird limbo between legitimate academic research and the gray-market peptide world.
Humanin
Discovered in 2001 from a cDNA library screen of surviving neurons in Alzheimer's disease brains. Humanin is a 24-amino-acid peptide also encoded in the mitochondrial genome. It has demonstrated cytoprotective effects against amyloid-beta toxicity, oxidative stress, and apoptosis across dozens of studies.
A 2020 Aging Cell paper showed that circulating Humanin levels decline with age and correlate inversely with cognitive decline markers. The Humanin analog HNG (S14G-Humanin) has shown neuroprotective effects at picomolar concentrations in vitro.
Why it is still underground: Despite nearly 25 years of research, no pharmaceutical company has brought a Humanin-based drug to clinical trials. The peptide's short half-life and delivery challenges make development difficult.
SS-31 (Elamipretide)
A tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that targets cardiolipin in the inner mitochondrial membrane. Unlike most compounds on this list, SS-31 actually has human clinical trial data. Stealth BioTherapeutics (now Larimar Therapeutics after restructuring) ran Phase II and III trials for Barth syndrome and primary mitochondrial myopathy.
The Barth syndrome trials showed improvements in the six-minute walk test and cardiac function. However, the Phase III TAZPOWER trial missed its primary endpoint in 2021, leading to an FDA Complete Response Letter.
Why it matters: SS-31 is the closest thing to a "validated" compound on this list. It has real pharmacokinetic data, safety profiles, and dose-response curves from human studies. The clinical failure was about efficacy endpoints, not safety catastrophes.
The Cognitive Frontier
Dihexa
A hexapeptide analog of angiotensin IV that acts as an agonist of the hepatocyte growth factor (HGF)/MET receptor system. A landmark 2013 study by Joseph Harding's group at Washington State University, published in the Journal of Pharmacology and Experimental Therapeutics, reported that Dihexa was "seven orders of magnitude more potent than BDNF" at promoting synaptogenesis in hippocampal cell cultures.
The reality check: That "seven orders of magnitude" figure gets thrown around constantly, but it compares apples to oranges -- Dihexa and BDNF work through completely different receptor systems. The compound has never been tested in humans. HGF/MET activation is also a known oncogenic pathway, which is a serious theoretical concern.
PE-22-28
A seven-amino-acid fragment of the spadin analog that acts as a TREK-1 channel blocker and putative BDNF mimetic. A 2019 study in Neuropharmacology showed antidepressant-like effects in mice and increased hippocampal BDNF levels after four days of treatment.
The reality check: One mouse study. That is essentially the entire evidence base. PE-22-28 went from a single preclinical paper to being sold by gray-market peptide vendors within months.
Why These Compounds Stay Underground
Several patterns explain why these peptides remain obscure:
- No commercial sponsor. Most are unpatentable short peptides. No pharma company will spend $1 billion on clinical trials for a molecule they cannot own exclusively.
- Single-lab syndrome. Many compounds have research from only one group. Without independent replication, the scientific community stays skeptical.
- Publication bias geography. A disproportionate amount of the data comes from Russian or Chinese journals that Western researchers rarely cite.
- Delivery challenges. Short peptides get chewed up by proteases in minutes. Oral bioavailability is essentially zero for most. Even subcutaneous injection gives unpredictable pharmacokinetics.
- Safety signals nobody is tracking. When there are no clinical trials, there is no systematic adverse event reporting. People using these compounds are running uncontrolled n=1 experiments with no safety net.
The Risk Gradient
Think of it this way. BPC-157 has hundreds of animal studies and reasonable mechanistic understanding. SS-31 has actual human clinical data. MOTS-c and Humanin have solid academic backing from multiple independent labs.
Then you have Dihexa with one research group and theoretical oncogenic risk. PE-22-28 with literally one mouse study. Khavinson peptides with decades of research but almost zero independent verification.
The further you go from established research, the more you are trusting the vendor's synthesis quality, the purity of what arrives in the mail, and your own body's ability to handle something that has never been systematically tested in humans.
What Advanced Users Should Actually Do
- Read the primary literature yourself. Do not rely on forum summaries or vendor descriptions. Pull the actual papers from PubMed and read the methods sections.
- Understand the difference between in-vitro, in-vivo, and clinical evidence. A cell culture finding is not a health benefit.
- Track the replication landscape. Has anyone besides the original lab confirmed the findings? If not, discount heavily.
- Consider the risk-reward honestly. Is the potential benefit worth being an unpaid test subject for an untested compound?
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, and nothing here should be interpreted as an endorsement or recommendation to use any of the compounds discussed. Many of these substances are not approved for human use by any regulatory agency. The research cited is preliminary, often preclinical, and subject to revision. Always consult a qualified healthcare professional before making decisions about your health. CompoundIQ Research assumes no liability for actions taken based on this content.